San Diego, CA, United States of America

Viacyte, Inc.


USPTO Granted Patents = 110

% Expired Patents = 5.5



Trademarks = 3

Forward Citations = 1,872

Loading Chart...
Loading Chart...

45 inventors (with patents filed for the assignee):

goldMedal Chad Green (42 out of 42 patents)

silverMedal Kevin Allen D'Amour (40 out of 47 patents)

bronzeMedal Laura A Martinson (38 out of 42 patents)

4.  Emmanuel Edward Baetge (38 out of 46 patents)

5.  Alan D Agulnick (35 out of 39 patents)

6.  Michael J Scott (24 out of 45 patents)

7.  Thomas C Schulz (22 out of 23 patents)

8.  Evert Kroon (20 out of 22 patents)

9.  Allan J Robins (19 out of 23 patents)

10.  Vincent So (18 out of 21 patents)

11.  Olivia Kelly (13 out of 14 patents)

12.  Susan Eliazer (11 out of 12 patents)

13.  Anne Bang (10 out of 11 patents)

14.  Erik D Olson (8 out of 19 patents)

15.  Giacomo Strollo (7 out of 12 patents)


Core Competencies:
Universal Donor Cells
Cell Encapsulation Device
Pluripotent Stem Cells
Pancreatic Endoderm Cells
Endocrine Cells
Human Serum Media
PDX1-positive Cells
Cryopreservation
Hormone Production
Implantable Devices
Cell Delivery Methods
3D Cell Assembly

110 patents:

Viacyte, Inc., based in San Diego, CA, specializes in innovative cell encapsulation technologies aimed at addressing diabetes through regenerative medicine. The company focuses on developing universal donor cells and advanced cell encapsulation devices that utilize pluripotent stem cells to create pancreatic endoderm and endocrine cells. Their research emphasizes the use of human serum media and PDX1-positive cells, alongside cryopreservation techniques, to enhance the viability and functionality of cell therapies for diabetes management.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Viacyte, Inc.
110 Patents

#56 in San Diego, CA

#786 in California

#3,472 in US

#7,151 in the World

San Diego, CA (US)
San Diego, CA, United States of America
Forward Citations = 1,872

45 inventors:

Please report any incorrect information to [email protected]
Loading…